Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree.
That just put a smile on my face. Cause I know it's coming IMO
We shall see those days again IMO.
I agree, absolutely. There are many things currently setting us up for .20 and beyond.
-REVENUES
-PARTNERSHIPS
-PHASE 3 CONTINUATION
-SHARE REPURCHASE PROGRAM
-MYOCELL SDF-1 JV
Amazing revenues that are growing exponentially. Amazing partnerships that are growing... Exponentially, as well.
Spot on. After the upcoming 10K I am confident I will be able to post here that "we BioHeart, are self sustaining" without using an "IMO"
http://investorstemcell.com/investing/biohearts-steadfast-commitment/
Today, Bioheart is a combination of distinct business enterprises. We estimate that the products and services we offer through US Stem Cell Training, Vetbiologics, and US Stem Cell Clinics has the potential, although we cannot provide assurances as to if and when it will be accomplished, to drive up to $100 million dollars in cumulative peak annual revenues. What we are establishing is a foundation of value in the products and services we are and plan to sell from US Stem Cell Training, Vetbiologics, and US Stem Cell clinics. Through our third quarter, as reported, we have increased year to date revenues from $56 thousand in 2013 to $1.6 million in 2014. Our strategy is to expand the revenues generated from each of these subsidiaries and to reinvest the profits we generate into our Bioheart clinical development pipeline. - See more at: http://investorstemcell.com/investing/biohearts-steadfast-commitment/#sthash.Ff6jbhap.dpuf
I wholeheartedly agree.
“Fundamental shifts in venture capital investment strategies where financial sponsorship is now directed toward commercial or near commercial enterprises has required Bioheart to adapt its mission combining immediate revenue generating opportunities with longer-term development programs. Accordingly, Bioheart has developed a multifaceted portfolio of revenue generating products and services in its US Stem Cell Training, Vetbiologics and US Stem Cell Clinic subsidiaries that will, if successful, financially support its clinical development programs. Our goal is to maximize shareholder value through the generation of short-term profits that increase cash flows and decrease the need for dilutive equity financings – a modern biotechnology company development strategy.” - See more at: http://investorstemcell.com/investing/biohearts-steadfast-commitment/#sthash.YFYe1D6N.dpuf
Excellent post.
The stock has to to sell for it to go in any direction.
Super MONSTER LOaDIng!!! Look at all the volume!! Everyone is jumping on the train before it takes off IMO
Actually... "Double up"
I will "double down" before the 10K
Things are happening, times are changing... BioHeart is at the forefront of the future of medical treatment.
This is great news!!!
Check the 8K that was released after the annual shareholders meeting, there's a slide there that discusses BioHearts future revenue potential beginning in 2015. The revenues will come from BioHearts 3 subsidiaries:
U.S. STEMCELL TRAINING
VETBIOLOGICS
U.S. STEM CELL CLINIC
IMO 100+ million is not far fetched at all. Also, stocks are based on a companies FUTURE growth. What did you think about BioHearts annual shareholders meeting and how they discussed the growth of the company and potential revenues?
It must be dilution! As I casually ignore the 100+ million dollar revenues year over year!
Lmao and then sunk in a blink of an eye to 28.95
Yeah I too would like to get the play by play when we're above .05 and beyond.
It's an update to the original release. I haven't read it so I don't know what the update entails.
Great stock to be in at these levels IMO. Over 30 partnerships, increased revenues over 1.5 million as of Q3, Phase 3 clinical trials, global leader in the stem cell and regenerative medicine biotech field. IMO.
http://www.bioheartinc.com/News-Events/NewsReleases
For anyone that wants to do some DD on BioHeart. I would suggest reading all the archived PR from the last 2 years. If you start from two years ago and work your way to the last PR you'll see the business plan unfold perfectly. IMO
Quote:
"WHY did BHRT do that if they don't plan to DILUTE, DILUTE and DILUTE? Why did they take the time and effort to specifically, massively increase the available share count out to 2 BILLION shares? Why? "
I disagree.
Quote:
"End of BHRT story the way I see it- they'll dilute out using every last one of the present 2 BILLION A/S if the past is any indicator and the current rate of massive dilution continues- I don't see anything that will change that IMO. They picked 2 BILLION for a reason IMO- they probably knew they were going to Magna and that alone was going to skyrocket the dilution among other things like massive shares to insiders, etc. "
I disagree
IMO he was referring to TNGN where the shareholders did not approve a proxy for more shares in order to dilute and as a result filed for bankruptcy.
Posted on BioHeart.com
Annual shareholders conference call
http://www.brainshark.com/brainshark/vu/?pi=587528900&dm=5&pause=1&appKey=77
Yes and when that happens, no one will want to sit this one out.
Yes they do! A green future IMO!
It's an automatic scheduled filing right?
Absolutely.
Just got an email!
U.S. Stem Cell Clinic now open in Sunrise Florida!
Now open in Sunrise, Florida!
Providing world-class stem cell therapy in-clinic
Platelet Rich Plasma Therapy
Adipose Derived Stem Cell Therapy
Bone Marrow Derived Stem Cell Therapy
Able to administer adult autologous stem cells via IV, IA, IM, intrathecal, and intradiscal deliveries to our patients in a minimally invasive outpatient procedure
Dr. Antonio Blanco is our medical director and oversees a medical staff experienced in the most advanced regenerative medicine and adult stem cell therapy techniques
Our Chief Science Officer is world-renowned stem cell scientist Kristin Comella, who is the chief scientific officer at Bioheart, Inc. and is recognized as a top 25 stem cell scientist world-wide
Kristin Comella has over 15 years of experience in regenerative medicine and was recently named number 24 according to Terrapin's 2013 list of the Top 50 Global Stem Cell Influencers. See below for the reference to the 'Top 50 Global Stem Cell Influencers' and to her biography.
Working with "clinics in Australia"
So far so good!!
Vetbiologics!! I had no idea we had that in place
"Active talks for partnership" for Myocell SDf1!!